Table 5 Factors associated with risk for PONV until noon the first postoperative day
Number of | Number of patients | Unadjusted OR | ||
|---|---|---|---|---|
patients | with PONV (%) | (CI) | p-value | |
Gender | ||||
Female | 42 | 20 (48%) | 2.33 (1.01–5.38) | 0.046 |
Male | 57 | 16 (28%) | ||
BMI | ||||
< 35 kg/m2 | 88 | 30 (34%) | 1.93 (0.52–7.20) | 0.32 |
≥ 35 kg/m2 | 10 | 5 (50%) | ||
History of PONV | ||||
Yes | 19 | 13 (68%) | 5.37 (1.82–15.8) | 0.003 |
No | 80 | 23 (29%) | ||
History of motion sickness | ||||
Yes | 19 | 8 (42%) | 1.35 (0.49–3.75) | 0.56 |
No | 80 | 28 (35%) | ||
Non-smoker | ||||
Yes | 98 | 36 (36%) | NA | 0.184 |
No | 1 | 1 (100%) | ||
Preoperative treatment with opioids | ||||
Yes | 12 | 4 (33%) | 0.90 (0.24–3.08) | 0.81 |
No | 87 | 32 (37%) | ||
COX-2 inhibitor in premedication | ||||
Yes | 9 | 3 (33%) | 0.86 (0.21–3.68) | 0.84 |
No | 90 | 33 (37%) | ||
Suboptimal PONV prophylaxis | ||||
Yes | 27 | 15 (56%) | 3.04 (1.22–7.57) | 0.015 |
No | 72 | 21 (29%) | ||
Type of prosthesis surgery | ||||
Hip | 78 | 27 (35%) | 0.71 (0.26–1.88) | 0.49 |
Knee | 21 | 9 (43%) | ||
Intrathecal morphine, dose | ||||
80–100 μg | 11 | 5 (45%) | 1.51 (0.42–5.42) | 0.79 |
120 μg | 76 | 27 (35%) | reference | |
140–200 μg | 12 | 4 (33%) | 0.91 (0.25–3.29) | |
Gabapentin given postoperatively | ||||
Yes | 36 | 13 (39%) | 1.22 (0.52–2.88) | 0.66 |
No | 63 | 23 (35%) | ||
Given oral or parenteral opioids until noon Day 1 | ||||
Yes | 97 | 35 (36%) | 0.56 (0.03–9.3) | 0.68 |
No | 2 | 1 (50%) | ||
Maximal NRS ≥5 for pain until noon Day 1. | ||||
Yes | 39 | 17 (44%) | 1.67 (0.72–3.84) | 0.23 |
No | 60 | 19 (32%) | ||